---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-010112"
form_type: "8-K"
ticker: "VKTX"
cik: "0001607678"
company_name: "Viking Therapeutics, Inc."
filed_at: "2023-03-28T23:59:59+00:00"
generated_at: "2026-06-17T12:50:52.701595+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Viking Therapeutics initiates Phase 1 study for oral GLP-1/GIP agonist VK2735; data expected H2 2023

## Summary
- Phase 1 trial of oral VK2735 tablet, dual GLP-1/GIP receptor agonist, in healthy adults with BMI ≥30.
- Randomized, double-blind, placebo-controlled study evaluating daily oral doses for 28 days.
- Primary objective: safety and tolerability; exploratory measures include body weight and plasma glucose.
- Top-line data anticipated in the second half of 2023.
- Prior subcutaneous Phase 1 showed up to 7.8% mean weight loss; Phase 2 for subcutaneous formulation planned for mid-2023.

## SEC filing metadata
- accession: 0000950170-23-010112
- form_type: 8-K
- ticker: VKTX
- cik: 0001607678
- company_name: Viking Therapeutics, Inc.
- filed_at: 2023-03-28T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1607678/000095017023010112/0000950170-23-010112-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1607678/000095017023010112/vktx-20230328.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-010112
- JSON: https://secwatch.observer/filing/0000950170-23-010112.json
- Plain text: https://secwatch.observer/filing/0000950170-23-010112.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.